GEN Exclusives

More »

GEN Poll

More »
May 24, 2012

Funding Early-Stage Companies

Biopharma giants eager to cut R&D costs but still restore depleted pipelines are starting to fill the gap left by retreating VC firms, launching new funds designed to invest in promising startups. For example, the $250 million fund created by Merck & Co. last year agreed to collaborate with Flagship Ventures this April. GlaxoSmithKline and Janssen contributed $50 million each toward a €150 million ($200 million) fund whose investment decisions will be made by majority partner Index Ventures, which is investing the other half. Russia’s $10 billion state-owned technology fund Rusnano and U.S. VC firm Domain Associates committed $760 million to support U.S. pharma, diagnostics, and medical device companies, create a manufacturing plant, and increase Russian drug development.

How much do you think newly established funds will succeed in helping startups?

A Lot
 
  28.9%
Somewhat
 
  46.7%
Not Much
 
  24.4%
Undecided
 
  0.0%

More Polls » View Results »

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?